Literature DB >> 30957901

Favorable response to apremilast in a patient with refractory psoriasis verrucosa.

Sari Okazaki1, Risa Osawa1, Hideki Nakajima1, Kimiko Nakajima1, Shigetoshi Sano1.   

Abstract

A 67-year-old man, who had been diagnosed with psoriasis 30 years prior, visited our hospital with a complaint of verrucous nodules in the lower legs, which had developed 15 years previously. We diagnosed him as having psoriasis verrucosa of the legs and plaque psoriasis of the torso. Because the lesions were resistant to topical glucocorticoids and vitamin D3 , a verrucous lesion in the right leg was treated with surgical ablation, which resulted in the development of generalized pustular psoriasis. After pustular lesions were cleared by systemic glucocorticoids and methotrexate, we treated him with etretinate and cyclosporin, but the verrucous lesions accompanied by chronic bacterial infection persisted over time. One year ago, treatment with recently-approved apremilast was started. It immediately attenuated the plaques and erythropapular lesions of the trunk. Surprisingly, the verrucous nodules of both legs showed reduction in size in 2 months.
© 2019 Japanese Dermatological Association.

Entities:  

Keywords:  apremilast; cyclic adenosine monophosphate; keratinocyte proliferation; phosphodiesterase 4 inhibitor; psoriasis verrucosa

Mesh:

Substances:

Year:  2019        PMID: 30957901     DOI: 10.1111/1346-8138.14877

Source DB:  PubMed          Journal:  J Dermatol        ISSN: 0385-2407            Impact factor:   4.005


  2 in total

Review 1.  Verrucous psoriasis in a male patient with a history of vulgar psoriasis: Case report and literature review

Authors:  Javier Hernández; Ana Ruiz; Carolina Mesa; Lina Rodríguez
Journal:  Biomedica       Date:  2021-09-22       Impact factor: 0.935

2.  Beneficial Impact of Apremilast on Palmoplantar Keratodermas.

Authors:  Kimiko Nakajima; Riho Nakajima; Hiroyuki Morisaka; Hideki Nakajima; Shigetoshi Sano
Journal:  Acta Derm Venereol       Date:  2021-04-26       Impact factor: 3.875

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.